TABLE 3.

Haplotype analyses for HIV-NRD development in European American and African American patients

	European Americans								African Americans
	Haplotype Frequency (%)		Allelic		Codominant		Dominant		Haplotype Frequency (%)		Allelic		Codominant		Dominant
Gene Haplotypes	cases (n=55)	controls (n=290)	OR	P	OR	P	OR	P	cases (n=54)	controls (n=180)	OR	P	OR	P	OR	P
CCR5
+.P1.+	43	34	1.45	0.07	1.90	0.04	1.89	0.04	22	25	0.88	0.63	0.87	0.57	0.79	0.46
RANTES
H1(G-C-T)	81	79	1.13	0.65	1.13	0.65	1.01	0.67	36	40	0.86	0.50	0.83	0.46	1.00	1.00
H2(A-C-T)	10	7	1.49	0.26	1.35	0.33	1.27	0.57	39	44	0.82	0.38	0.87	0.46	0.70	0.25
H3(A-C-C)	9	14	0.61	0.16	0.61	0.16	0.63	0.22	25	17	1.67	0.05	1.63	0.06	2.12	0.02
IL-10a	(n=55)	(n=290)							(n=50)	(n=172)
HG1	32	21	1.74	0.01	1.70	0.02	2.05	0.01	38	39	0.96	0.86	0.96	0.87	0.95	0.65
HG2	30	30	0.99	0.97	0.99	0.97	0.95	0.86	28	28	0.99	0.97	0.99	0.97	1.01	0.97
HG3	38	49	0.66	0.05	0.67	0.06	0.71	0.26	33	32	1.10	0.72	1.09	0.72	1.32	0.39

Adjusting the models for square root of nadir CD4+ T-cell cell count, highest log₁₀HIV-1 load, age, and gender does not significantly change the results.

^aHG1, HG2 and HG3 correspond to the combined proximal promoter IL-10 haplotypes (see Figure 1 for details).